Zydus Cadila has received the final approval from the USFDA to market Cholestyramine for Oral Suspension USP, 4 grams per scoopful.
 
It is indicated as an adjunctive therapy to the diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine  will be produced at the group’s formulations manufacturing facility at Baddi. 
 
The group now has more than 110 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 5.5, or 1.21%, to trade at Rs 458.85. The total volume of shares traded was 26,129 at the BSE (10.33 a.m., Thursday).